New combo therapy targets rare lung cancer mutation
NCT ID NCT07314216
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study tests a new drug (firmonertinib) combined with radiation therapy for people with a specific type of stage III lung cancer that cannot be removed by surgery. The cancer must have a rare change in the EGFR gene. The goal is to see if the combination can delay cancer growth. About 15 adults aged 18-75 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR UNCOMMON MUTATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410013, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may let cancer patients take safe breaks from immunotherapy
- New hope for lung cancer patients with brain-spread disease
- Experimental combo for tough cancers shows early promise, but trial halted
- Lung cancer combo trial halted early – too few patients to draw conclusions
- Real-World study tracks Durvalumab's safety and effectiveness in russian lung cancer patients
- New hope for rare lung cancer: targeted drug trial launches